Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 3 boards, counting each seat separately. Longest: Sagimet Biosciences Inc., 3 years.
Sagimet Biosciences Inc.
Director
Ardelyx Inc.
Director
ArriVent BioPharma Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 16, 2026 | Ardelyx Inc. | Grant or award | +26,455 | — | — |
| Jun 18, 2025 | Ardelyx Inc. | Grant or award | +15,235 | — | — |
| Apr 28, 2025 | Ardelyx Inc. | Grant or award | +42,056 | — | — |
| Dec 10, 2024 | Gilead Sciences Inc. | Option exercise | +3,820 | — | — |
| Dec 10, 2024 | Gilead Sciences Inc. | Shares withheld for tax | −1,771 | $92.34 | $163,534 |
| Nov 27, 2024 | Gilead Sciences Inc. | Option exercise | +57,294 | $57.92 | $3,318,468 |
| Nov 27, 2024 | Gilead Sciences Inc. | Option exercise | +88,119 | $65.38 | $5,761,220 |
| Nov 27, 2024 | Gilead Sciences Inc. | Open-market sale | −57,294 | $91.79 | $5,259,016 |
| Nov 27, 2024 | Gilead Sciences Inc. | Open-market sale | −88,119 | $92.00 | $8,106,948 |
| Nov 27, 2024 | Gilead Sciences Inc. | Open-market sale | −5,200 | $91.80 | $477,360 |
| Nov 27, 2024 | Gilead Sciences Inc. | Open-market sale | −3,199 | $91.80 | $293,668 |
| Nov 27, 2024 | Gilead Sciences Inc. | Open-market sale | −10,399 | $92.00 | $956,708 |
| Nov 6, 2024 | Gilead Sciences Inc. | Option exercise | +25,000 | $57.92 | $1,448,000 |
| Nov 6, 2024 | Gilead Sciences Inc. | Open-market sale | −20,590 | $91.50 | $1,883,985 |
| Nov 6, 2024 | Gilead Sciences Inc. | Open-market sale | −5,000 | $91.50 | $457,500 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.